Patients with questionable past reactions should obtain detailed medical records to clarify whether the response was a true allergy versus expected side effects like nausea or injection-site irritation
A double-blind, randomized phase 2 study comparing various doses (1, 5, 10, 15 mg) of once weekly tirzepatide, dulaglutide (1.5 mg) and placebo, in patients with T2DM, showed tirzepatide was superior on weight loss and glucose-lowering compared to both dulaglutide and placebo [52]
[Glutathione and eye diseases] [PMID: 5461838] Laboratory literature summary: [Glutathione and eye diseases]
doi:10.1056/NEJMoa2511774 FDA approves first new molecular entity under National Priority Voucher Program
For brokers and benefits leaders, this raises an important question: How can employers still support employee weight and metabolic health when GLP-1 medications are not part of the benefits strategy